Epigenetic mechanisms leading to overexpression of HMGA proteins in human pituitary adenomas

Frontiers of Medicine

Volumn 2, Issue , 2015, Pages

  D’Angelo, Daniela ^a   Esposito, Francesco ^a   Fusco, Alfredo ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

HMGA proteins; Long non coding rna; MicroRNAs; Pituitary tumors; Pseudogenes

Indexed keywords

EID: 84979030750     PISSN: 20950217     EISSN: 20950225     Source Type: Journal    
DOI: 10.3389/fmed.2015.00039     Document Type: Article

References (54)

1. Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, et al. The prevalence of pituitary adenomas: a systematic review. Cancer (2004) 101:613-9. doi:10.1002/cncr.20412
2. Kopczak A, Renner U, Karl Stalla G. Advances in understanding pituitary tumors. FlOOOPrime Rep (2014) 6:5. doi:10.12703/P6-5
3. Trouillas J. In search of a prognostic classification of endocrine pituitary tumors. Endocr Pathol (2014) 25:124-32. doi:10.1007/sl2022-014-9322-y
4. Melmed S. Pathogenesis of pituitary tumors. Nat Rev Endocrinol (2011) 7:257-66. doi:10.1038/nrendo.2011.40
5. Gadelha MR, Trivellin G, Hernández Ramírez LC, Korbonits M. Genetics of pituitary adenomas. Front Hortn Res (2013) 41:111-40. doi:10.1159/000345673
6. Pei L, Melmed S. Isolation and characterization of a pituitary tumor- transforming gene (PTTG). Mol Endocrinol (1997) 11:433-41. doi:10.1210/mend.11.4.9911
7. Yu R, Melmed S. Pituitary tumor transforming gene: an update. Front Hortn Res (2004) 32:175-85.
8. Zhang X, Sun H, Danila DC, Johnson SR, Zhou Y, Swearingen B, et al. Loss of expression of GADD45 gamma, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis. J Clin Endocrinol Metab (2002) 87:1262-7. doi:10.1210/jc.87.3.1262
9. Quereda V, Malumbres M. Cell cycle control of pituitary development and disease, J Mol Endocrinol (2009) 42:75-86. doi:10.1677/JME-08-0146
10. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA. Effects of an Rb mutation in the mouse. Nature (1992) 359:295-300. doi:10.1038/359295a0
11. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27Kipl-deficient mice. Cell (1996) 85:733-44. doi:10.1016/S0092-8674(00)81239-8
12. Franklin DS, Godfrey VL, Lee H, Kovalev GI, Schoonhoven R, Chen-Kiang S, et al. CDK inhibitors pl8(INK4c) and p27(Kipl) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev (1998) 12:2899-911. doi:10.1101/gad.12.18.2899
13. Reincke M, Sbiera S, Hayakawa A, Theodoropoulou M, Osswald A, Beuschlein F, et al. Mutations in the deubiquitinase gene USP8 cause Cushing’s disease. Nat Genet (2015) 47(l):31-8. doi:10.1038/ng.3166
14. Ma Z-Y, Song Z-J, Chen J-H, Wang Y-F, Li S-Q, Zhou L-F, et al. Recurrent gain- of-function USP8 mutations in Cushing’s disease. Cell Res (2015) 25(3):306-17. doi:10.1038/cr.2015.20
15. Reeves R, Nissen MS. The A.T-DNA-binding domain of mammalian high mobility group I chromosomal proteins. A novel peptide motif for recognizing DNA structure. J Biol Chem (1990) 265:8573-82.
16. Abdulkadir SA, Krishna S, Thanos D, Maniatis T, Strominger JL, Ono SJ. Functional roles of the transcription factor Oct-2A and the high mobility group protein I/Y in HLA-DRA gene expression. J Exp Med (1995) 182:487-500. doi:10.1084/jem.182.2.487
17. Lehming N, Thanos D, Brickman JM, Ma J, Maniatis T, Ptashne M. An HMG- like protein that can switch a transcriptional activator to a repressor. Nature (1994) 371:175-9. doi:10.1038/371175a0
18. Thanos D, Du W, Maniatis T. The high mobility group protein HMG I(Y) is an essential structural component of a virus-inducible enhancer complex. Cold Spring Harb Symp Quant Biol (1993) 58:73-81. doi:10.1101/SQB.1993.058.01.011
19. Fedele M, Fusco A. HMG A and cancer. Biochim Biophys Acta (2010) 1799:48-54. doi:10.1016/j.bbagrm.2009.11.007
20. Berlingieri MT, Manfioletti G, Santoro M, Bandiera A, Visconti R, Gian- cotti V, et al. Inhibition of HMGI-C protein synthesis suppresses retrovirally induced neoplastic transformation of rat thyroid cells. Mol Cell Biol (1995) 15: 1545-53.
21. Wood LJ, Maher JF, Bunton TE, Resar LMS. The oncogenic properties of the HMG-I gene family the oncogenic properties of the HMG-I gene family 1. Cancer Res (2000) 60(15):4256-61.
22. Baldassarre G, Fedele M, Battista S, Vecchione A, Klein-Szanto AJ, Santoro M, et al. Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL- 15 pathway. Proc Natl Acad Sci USA (2001) 98:7970-5. doi:10.1073/pnas.141224998
23. Fedele M, Battista S, Kenyon L, Baldassarre G, Fidanza V, Klein-Szanto AJP, et al. Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene (2002) 21:3190-8. doi:10.1038/sj.onc.1205428
24. Fedele M, Pentimalli F, Baldassarre G, Battista S, Klein-Szanto AJP, Kenyon L, et al. Transgenic mice overexpressing the wild-type form of the HMGAl gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. Oncogene (2005) 24:3427-35. doi:10.1038/sj.onc.1208501
25. Ashar HR, Fejzo MS, Tkachenko A, Zhou X, Fletcher JA, Weremowicz S, et al. Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains. Cell (1995) 82:57-65. doi:10.1016/0092-8674(95)90052-7
26. Schoenmakers EF, Wanschura S, Mols R, Bullerdiek J, Van den Berghe H, Van de Ven WJ. Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours. Nat Genet (1995) 10:436-44. doi:10.1038/ng0895-436
27. Finelli P, Pierantoni GM, Giardino D, Losa M, Rodeschini O, Fedele M, et al. The high mobility group A2 gene is amplified and overexpressed in human prolactinomas. Cancer Res (2002) 62:2398-405.
28. Pierantoni GM, Finelli P, Valtorta E, Giardino D, Rodeschini O, Esposito F, et al. High-mobility group A2 gene expression is frequently induced in non-functioning pituitary adenomas (NFPAs), even in the absence of chromosome 12 polysomy. Endocr Relat Cancer (2005) 12:867-74. doi:10.1677/erc.l.01049
29. Evans C-O, Moreno CS, Zhan X, McCabe MT, Vertino PM, Desiderio DM, et al. Molecular pathogenesis of human prolactinomas identified by gene expression profiling, RT-qPCR, and proteomic analyses. Pituitary (2008) 11:231-45. doi:10.1007/s11102-007-0082-2
30. De Martino I, Visone R, Wierinckx A, Palmieri D, Ferraro A, Cappabianca P, et al. HMGA proteins up-regulate CCNB2 gene in mouse and human pituitary adenomas. Cancer Res (2009) 69:1844-50. doi:10.1158/0008-5472.CAN-08-4133
31. Šteno A, Bocko J, Rychlý B, Chorváth M, Celec P, Fabian M, et al. Nonfunctioning pituitary adenomas: association of Ki-67 and HMGA-1 labeling indices with residual tumor growth. Acta Neurochir (Wien) (2014) 156:451-61. doi:10.1007/S00701-014-1993-0
32. Fedele M, Visone R, De Martino I, Troncone G, Palmieri D, Battista S, et al. HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell (2006) 9:459-71. doi:10.1016/j.ccr.2006.04.024
33. Vallone D, Battista S, Pierantoni GM, Fedele M, Casalino L, Santoro M, et al. Neoplastic transformation of rat thyroid cells requires the junB and fra-1 gene induction which is dependent on the HMGI-C gene product. EMBO f (1997) 16:5310-21. doi:10.1093/emboj/16.17.5310
34. Palmieri D, Valentino T, De Martino I, Esposito F, Cappabianca P, Wierinckx A, et al. PITl upregulation by HMGA proteins has a role in pituitary tumorigenesis. Endocr Relat Cancer (2012) 19:123-35. doi:10.1530/ERC-11-0135
35. Fedele M, Palmieri D, Fusco A. HMGA2: a pituitary tumour subtype- specific oncogene? Mol Cell Endocrinol (2010) 326:19-24. doi:10.1016/j.mce.2010.03.019
36. Wang EL, Qian ZR, Rahman MM, Yoshimoto K, Yamada S, Kudo E, et al. Increased expression of HMGAl correlates with tumour invasiveness and proliferation in human pituitary adenomas. Histopathology (2010) 56:501-9. doi:10.1111/j.l365-2559.2010.03495.x
37. Dermitzakis ET, Reymond A, Antonarakis SE. Conserved non-genic sequences - an unexpected feature of mammalian genomes. Nat Rev Genet (2005) 6:151-7. doi:10.1038/nrgl527
38. Bartel DP. microRNAs: target recognition and regulatory functions. Cell (2009) 136:215-33. doi:10.1016/j.cell.2009.01.002
39. Bentwich I. Prediction and validation of microRNAs and their targets. FEBS Lett (2005) 579:5904-10. doi:10.1016/j.febslet.2005.09.040
40. Dong H, Lei J, Ding L, Wen Y, Ju H, Zhang X. microRNA: function, detection, and bioanalysis. Chern Rev (2013) 113:6207-33. doi:10.1021/cr300362f
41. Di Leva G, Garofalo M, Croce CM. microRNAs in cancer. Atniu Rev Pathol (2014) 9:287-314. doi:10.1146/annurev-pathol-012513-104715
42. Qian ZR, Asa SL, Siomi H, Siomi MC, Yoshimoto K, Yamada S, et al. Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clin- icopathological features in pituitary adenomas. Mod Pathol (2009) 22:431-41. doi:10.1038/modpathol.2008.202
43. Palmieri D, DAngelo D, Valentino T, De Martino I, Ferraro A, Wierinckx A, et al. Down regulation of HMG A-targeting microRNAs has a critical role in human pituitary tumorigenesis. Oncogene (2012) 31:3857-65. doi:10.1038/onc.2011.557
44. D’Angelo D, Palmieri D, Mussnich P, Roche M, Wierinckx A, Raverot G, et al. Altered microRNA expression profile in human pituitary GH adenomas: down- regulation of miRNA targeting HMGAl, HMGA2, and E2F1. J Clin Endocrinol Metab (2012) 97:E1128-38. doi:10.1210/jc.2011-3482
45. Leone V, Langella C, DAngelo D, Mussnich P, Wierinckx A, Terracciano L, et al. miR-23b and miR- 130b expression is downregulated in pituitary adenomas. Mol Cell Endocrinol (2014) 390:1-7. doi:10.1016/j.mce.2014.03.002
46. Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol (2012) 9:703-19. doi:10.4161/rna.20481
47. Mighell AJ, Smith NR, Robinson PA, Markham AF. Vertebrate pseudogenes. FEBS Lett (2000) 468:109-14. doi:10.1016/S0014-5793(00)01199-6
48. Balakirev ES, Ayala FJ. Pseudogenes: are they “junk” or functional DNA? Annu Rev Genet (2003) 37:123-51. doi:10.1146/annurev.genet.37.040103.103949
49. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP. A coding- independent function of gene and pseudogene mRNAs regulates tumour biology. Nature (2010) 465:1033-8. doi:10.1038/nature09144
50. Esposito F, De Martino M, Petti MG, Forzati F, Tornincasa M, Federico A, et al. HMGA 1 pseudogenes as candidate proto-oncogenic competitive endogenous RNAs. Oncotarget (2014) 5(18):8341-54.
51. Esposito F, De Martino M, D’Angelo D, Mussnich P, Raverot G, Jaffrain- Rea ML, et al. HMGAl-pseudogene expression is induced in human pituitary tumors. Cell Cycle (2015) 14(9):1471-5. doi:10.1080/15384101.2015.1021520
52. Esposito F, De Martino M, Forzati F, Fusco A. HMGAl-pseudogene overexpression contributes to cancer progression. Cell Cycle (2014) 13:3636-9. doi:10.4161/15384101.2014.974440
53. Kung JTY, Colognori D, Lee JT. Long noncoding RNAs: past, present, and future. Genetics (2013) 193:651-69. doi:10.1534/genetics.ll2.146704
54. D’Angelo D, Borbone E, Palmieri D, Uboldi S, Esposito F, Frapolli R, et al. The impairment of the high mobility group A (HMGA) protein function contributes to the anticancer activity of trabectedin. Eurf Cancer (2013) 49:1142-51. doi:10.1016/j.ejca.2012.10.014